Pharmacologic Treatment for the Core Deficits and Associated Symptoms of Autism in Children

Journal of Pediatric Health Care

Volumn 23, Issue 2, 2009, Pages 75-89

  West, Lis ^a   Waldrop, Julee ^a   Brunssen, Susan ^a  

^a NONE

Author keywords

Autism; autism management; autism symptoms; core deficits; parent education; pharmacologic; side effects

Indexed keywords

ANTICONVULSIVE AGENT; NEUROLEPTIC AGENT;

ARTICLE; AUTISM; CHILD; CONTINUING EDUCATION; HUMAN; PATHOPHYSIOLOGY;

ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; AUTISTIC DISORDER; CHILD; EDUCATION, CONTINUING; HUMANS;

EID: 60249083550     PISSN: 08915245     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pedhc.2008.12.001     Document Type: Article

References (42)

1. Aman M., Van Bourgondien M., Wolford P., and Sarphare G. Psychotropic and anticonvulsant drugs in subjects with autism: Prevalence and patterns of use. Journal of the American Academy of Child and Adolescent Psychiatry 34 (1995) 1672-1681
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. (1994), American Psychiatric Association, Washington, DC
3. Arnold E., Aman M., Cook A., Witwer A., Hall K., Thompson S., et al. Atomoxetine for hyperactivity in autism spectrum disorders: Placebo-controlled crossover pilot trial. Journal of the American Academy of Child and Adolescent Psychiatry 45 (2006) 1196-1205
4. Campbell M., Armenteros J., Malone R., Adams P., Eisenberg Z., and Overall J. Neuroleptic-related dyskinesias in autistic children: A prospective, longitudinal study. Journal of the American Academy of Child and Adolescent Psychiatry 26 (1997) 835-843
5. Centers for Disease Control and Prevention. CDC releases new data on autism spectrum disorders from multiple communities in the United States (CDC Media Relations). Retrieved March 21, 2007. from (2007). http://www.cdc.gov/od/oc/media/pressrel/2007/r070208.htm
6. Eli Lilly. Zyprexa (package insert) (2006), Eli Lilly and Company, Indianapolis, IN
7. Elia J., Borcherding G., Rapoport J., and Keysor C. Methylphenidate and dextroamphetamine treatments of hyperactivity: Are there true nonresponders?. Psychiatry Research 36 (1991) 141-155
8. Food and Drug Administration. FDA approves the first drug to treat irritability associated with autism, Risperdal. FDA News (2006). http://www.fda.gov/bbs/topics/NEWS/2006/NEW01485.html Retrieved December 30, 2006, from
9. Findling R., Maxwell K., and Wiznitzer M. An open clinical trial of risperidone monotherapy in young children with autistic disorder. Psychopharmacology Bulletin 33 (1997) 155-159
10. Findling R., McNamara N., Gracious B., O'Riordan M., Reed M., Demeter C., et al. Quetiapine in nine youths with autistic disorder. Journal of Child and Adolescent Psychopharmacology 14 (2004) 287-294
11. Fombonne E. Epidemiological surveys of autism and other pervasive developmental disorders: An update. Journal of Autism and Developmental Disorders 33 (2003) 365-382
12. Greenhill L., Swanson J., Vitiello B., Davies M., Clevenger W., Wu M., et al. Impairment and deportment responses to different methylphenidate doses in children with ADHD: The MTA titration trial. Journal of the American Academy of Child and Adolescent Psychiatry 40 (2001) 180-187
13. Gringras P. Practical paediatric psychopharmacological prescribing in autism: The potential and the pitfalls. Autism 4 (2000) 229-247
14. Handen B., Johnson C., and Lubetsky M. Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. Journal of Autism and Developmental Disorders 30 (2000) 245-255
15. Hellings J., Weckbaugh M., Nickel E., Cain S., Zarcone J., Reese M., et al. A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology 15 (2005) 682-692
16. Hollander E., Phillips A., Chaplin W., Zagursky K., Novotny S., Wasserman S., et al. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology 30 (2005) 582-589
17. Hollander E., Soorya L., Wasserman S., Esposito K., Chaplin W., and Anagnostou E. Divalproex sodium vs. placebo in the treatment of repetitive behaviors in autism spectrum disorder. International Journal of Neuropsychopharmacology 9 (2005) 209-213
18. Hollander W., Wasserman S., Swanson E., Chaplin W., Schapiro M., Zagursky K., et al. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. Journal of Child and Adolescent Psychopharmacology 16 (2006) 541-548
19. King B., Wright M., Handen B., Sikich L., Zimmerman A., McMahon W., et al. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry 40 (2001) 658-665
20. Lacy C., Armstrong L., Goldman M., and Lance L. Drug information handbook: A comprehensive resource for all clinicians and health care professionals. 14th ed. (2006), Lexi-Comp, Inc, Hudson, OH
21. Langworthy-Lam K., Aman M., and Van Bourgondien M. Prevalence and patterns of use of psychoactive medicines in individuals with autism in the Autism Society of North Carolina. Journal of Child and Adolescent Psychopharmacology 12 (2002) 311-321
22. Lecavalier L. Behavioral and emotional problems in young people with pervasive developmental disorders: Relative prevalence, effects of subject characteristics, and empirical classification. Journal of Autism and Developmental Disorders 36 (2006) 1101-1114
23. Malone R., Cater J., Sheikh R., Choudhury M., and Delaney M. Olanzapine versus haloperidol in children with autistic disorder: An open pilot study. Journal of the American of Child and Adolescent Psychiatry 40 (2001) 887-894
24. Malone R., Maislin G., Choudhury M., Gifford C., and Delaney M. Risperidone treatment in children and adolescents with autism: Short- and long-term safety and effectiveness. Journal of the American Academy of Child and Adolescent Psychiatry 41 (2002) 140-147
25. Martin A., Koenig K., Anderson G., and Scahill L. Low-dose Fluvoxamine treatment of children and adolescents with pervasive developmental disorders: A prospective, open-label study. Journal of Autism and Developmental Disorders 33 (2003) 77-85
26. Martin A., Koenig K., Scahill L., and Bregman J. Open-label quetiapine in the treatment of children and adolescents with autistic disorder. Journal of Child and Adolescent Psychopharmacology 9 (1999) 99-107
27. McDougle C., Holmes J., Bronson M., Anderson G., Volkmar F., Price L., et al. Risperidone treatment of children and adolescents with pervasive developmental disorders: A prospective, open-label study. Child and Adolescent Psychiatry 26 (1997) 685-693
28. McDougle C. Ask the Editor. Journal of Autism and Developmental Disorders 34 (2004) 593-594
29. McDougle C.J., Scahill L., Aman M.G., McCracken J.T., Tierney E., Davies M., et al. Risperidone for the core symptom domains of autism: Results from the study by the Autism Network of the Research Units on Pediatric Psychopharmacology. American Journal of Psychiatry 162 (2005) 1142-1148
30. Owley T., Salt J., Guter S., Grieve A., Walton L., Ayuyao N., et al. A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology 16 (2006) 517-524
31. Owley T., Walton L., Salt J., Guter S., Winnega M., Leventhal B., et al. An open-label trial of escitalopram in pervasive developmental disorders. Journal of the American Academy of Child and Adolescent Psychiatry 44 (2005) 343-348
32. Perry R., Pataki C., Munoz-Silva D., Armenteros J., and Silva R. Risperidone in children and adolescents with pervasive developmental disorder: Pilot trial and follow-up. Journal of Child and Adolescent Psychopharmacology 7 (1997) 167-179
33. Posey D., Erickson C., Stigler K., and McDougle C. The use of serotonin reuptake inhibitors in autism and related disorders. Journal of Child and Adolescent Psychopharmacology 16 (2006) 181-186
34. Posey D., Wiegand R., Wilkerson J., Maynard M., Stigler K., and McDougle C. Open-label atomoxetine for attention-deficit/hyperactivity disorder symptoms associated with higher-functioning pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology 16 (2006) 599-610
35. Research Units on Pediatric Psychopharmacology Autism Network. Risperidone in children with autism and serious behavioral problem. New England Journal of Medicine 347 (2002) 314-321
36. Research Units on Pediatric Psychopharmacology Autism Network. Risperidone treatment of autistic disorder: Longer-term benefits and blinded discontinuation after 6 months. American Journal of Psychiatry 162 (2005) 1361-1369
37. Research Units on Pediatric Psychopharmacology Autism Network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Archives of General Psychiatry 62 (2005) 1266-1274
38. Scahill L., Aman M., McDougle M., McCracken J., Tierney E., Dziura J., et al. A prospective open trial of guanfacine in children with pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology 16 (2006) 589-598
39. Scahill L., Chappell P., Kim Y., Schultz R., Katsovich L., Shepherd E., et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention-deficit hyperactivity disorder. American Journal of Psychiatry 158 (2001) 1067-1074
40. Taketomo C.K., Taketomo C., Hodding J.H., and Kraus D.M. Lexi-Comp's pediatric dosage handbook. 13th ed. (2006), Lexi-Comp Inc, Hudson, OH
41. Wasserman S., Iyengar R., Chaplin W., Watner D., Waldoks S., Anagnostou E., et al. Levetiracetam versus placebo in childhood and adolescent autism: A double-blind placebo-controlled study. International Clinical Psychopharmacology 21 (2006) 363-367
42. West L., and Waldrop J. Risperidone use in the treatment of behavioral symptoms in children with autism. Pediatric Nursing 32 (2006) 545-549